Medvest Capital

An investment committee composed of David Cash, Todd Saunders, and David Menkhaus makes all investment decisions. The committee evaluates deals directly, relying on the members' combined expertise in device development, healthcare real estate, and regulatory law rather than delegating to a separate management company.

The firm sources opportunities largely through the clinical and commercial networks of its principals. Todd Saunders' tenure at SpineFrontier and Thomspon Minimally Invasive Surgery, combined with David Menkhaus's extensive legal representation of ambulatory surgery centers and physician groups, creates a referral network grounded in operating and clinical circles.

Medvest Capital does not publicly disclose a commingled fund structure. Its principals serve directly on portfolio company boards, suggesting a concentrated, direct investment model where each deal receives hands-on operational, regulatory, and real estate support from the committee.

Medvest Capital targets early-stage medical device companies, spanning seed through growth equity. The firm states it invests in startups that have not yet reached commercialization, stepping in with capital, compliance navigation, and strategic guidance to bridge the gap from concept to market clearance.

Medvest Capital's stated mandate is limited to medical devices. It does not indicate activity in biotech pharmaceuticals, digital health software, or healthcare services unrelated to a physical device component. Its principals' backgrounds reinforce this narrow focus on hardware-based interventions.